MSA Capital
和玉资本
MSA Capital (和玉资本) is a venture capital firm active in China's biotech and healthcare sector, appearing in elsewhere's corpus primarily as a co-investor in life-science deals from 2021–2022 . It participated in the angel round of Yanming Biotech alongside Lilly Asia Ventures and FreeS Capital in July 2021, joined the nearly $100 million Series B of Singleron Biotech later that year, and came in as a new investor in Vitaeon Therapeutics' $200 million Series B in August 2022, alongside entities such as Abu Dhabi Investment Authority's subsidiary and CBC Group . elsewhere's corpus does not contain further detail on the firm's founding, team, or fund scale.
AI-generated — may contain errors, please verify.
Coverage
Vitaeon Therapeutics Completes $200 Million Series B Round to Develop Transformative Therapies for Aging-Related Degenerative Diseases
Transforming the treatment paradigm for age-related degenerative diseases, improving quality of life for millions of patients and families worldwide.
3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
FreeS Family Funding News · July | PatPat, Yanming Biotech, Qbit, and Innostar Secure Financing
We've also released three short videos this issue — follow us to check them out.
